{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:02:01Z","timestamp":1787724121073,"version":"build-2784847793"},"reference-count":125,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1124\/dmd.119.087270","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T18:05:11Z","timestamp":1566497111000},"page":"1206-1221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2994-0728","authenticated-orcid":false,"given":"Diane","family":"Ramsden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niresh","family":"Hariparsad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane R.","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mohutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Parrott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"Tweedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.119.087270_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2165\/00003088-197803020-00002","article-title":"Clinical pharmacokinetics of rifampicin","volume":"3","author":"Acocella","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.119.087270_bib2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.115.066845","article-title":"Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model","volume":"44","author":"Almond","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/psp4.12275","article-title":"Comprehensive PBPK model of rifampicin for quantitative prediction of complex drug-drug interactions: CYP3a\/2C9 induction and OATP inhibition effects","volume":"7","author":"Asaumi","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev.pharmtox.45.120403.100004","article-title":"Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions","volume":"45","author":"Atkins","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.119.087270_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00228-006-0127-x","article-title":"Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine","volume":"62","author":"Backman","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.118.253062","article-title":"Comprehensive evaluation of the utility of 20 endogenous molecules as biomarkers of OATP1B inhibition compared with rosuvastatin and coproporphyrin I","volume":"368","author":"Barnett","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.087270_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/cpt.983","article-title":"Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modeling and simulation","volume":"104","author":"Barnett","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00228-004-0746-z","article-title":"Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide","volume":"60","author":"Bidstrup","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.dmpk.2018.01.004","article-title":"Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: a siRNA-silencing-based approach","volume":"33","author":"Chan","year":"2018","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.119.087270_bib10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/00498254.2016.1222640","article-title":"An exposure-response analysis based on rifampin suggests CYP3A4 induction is driven by AUC: an in vitro investigation","volume":"47","author":"Chang","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.119.087270_bib11","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1124\/dmd.109.026997","article-title":"Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro","volume":"37","author":"Chang","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-0711-5-3","article-title":"Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor","volume":"5","author":"Chen","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1124\/dmd.119.087270_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200847010-00006","article-title":"Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects","volume":"47","author":"Darwish","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.119.087270_bib14","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1517\/17425250802500028","article-title":"Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both?","volume":"4","author":"Davydov","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.119.087270_bib15","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.biochem.5b00079","article-title":"Mechanism of drug-drug interactions mediated by human cytochrome P450 CYP3A4 monomer","volume":"54","author":"Denisov","year":"2015","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.119.087270_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0016-5085(90)90963-2","article-title":"Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450","volume":"99","author":"Diaz","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.119.087270_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/abbi.1997.0525","article-title":"Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation","volume":"350","author":"Domanski","year":"1998","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.119.087270_bib18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2165\/00003088-200746120-00004","article-title":"Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies","volume":"46","author":"Eberl","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.119.087270_bib19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1124\/dmd.117.076851","article-title":"Physiologically based pharmacokinetic model predictions of panobinostat (LBH589) as a victim and perpetrator of drug-drug interactions","volume":"45","author":"Einolf","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/dmd.113.054932","article-title":"Cytochrome p450 inhibitory properties of common efflux transporter inhibitors","volume":"42","author":"Englund","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib21","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jps.2600840305","article-title":"Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A induction","volume":"84","author":"Fleishaker","year":"1995","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.119.087270_bib24","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00008571-200310000-00003","article-title":"Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women","volume":"13","author":"Floyd","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.119.087270_bib22","unstructured":"Food and Drug Administration (FDA) (2017) Clinical drug interaction studies- study design, data analysis, and clinical implications guidance for industry. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD. https:\/\/www.fda.gov\/media\/108130\/download"},{"issue":"4","key":"10.1124\/dmd.119.087270_bib125","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/hep.510240407","article-title":"Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin","volume":"24","author":"Fromm","year":"1996","journal-title":"Hepatology"},{"key":"10.1124\/dmd.119.087270_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2125.1989.tb03516.x","article-title":"The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction","volume":"28","author":"Ged","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1124\/dmd.110.032649","article-title":"Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data","volume":"38","author":"Gertz","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib27","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.40.7.1715","article-title":"Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers","volume":"40","author":"Gillum","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.119.087270_bib28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0009-9236(03)00187-5","article-title":"The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity","volume":"74","author":"Gorski","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib29","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1177\/0091270008323754","article-title":"Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs","volume":"48","author":"Greenblatt","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s002280100277","article-title":"The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients","volume":"57","author":"Grub","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/dmd.117.078006","article-title":"Simultaneous physiologically based pharmacokinetic (PBPK) modeling of parent and active metabolites to investigate complex CYP3A4 drug-drug interaction potential: a case example of midostaurin","volume":"46","author":"Gu","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jcph.988","volume":"58","author":"Gupta","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib33","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1124\/dmd.116.074567","article-title":"Considerations from the IQ induction working group in response to drug-drug interaction guidance from regulatory agencies: focus on downregulation, CYP2C induction, and CYP2B6 positive control","volume":"45","author":"Hariparsad","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib34","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1124\/dmd.105.008904","article-title":"Factors influencing midazolam hydroxylation activity in human liver microsomes","volume":"34","author":"He","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib35","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s40262-018-0635-8","article-title":"Predictive performance of physiologically-based pharmacokinetic models in predicting drug-drug interactions involving enzyme modulation","volume":"57","author":"Hsueh","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.119.087270_bib36","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1124\/dmd.109.031328","article-title":"Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis","volume":"38","author":"Hu","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1124\/dmd.116.072025","article-title":"Managing the risk of CYP3A induction in drug development: a strategic approach","volume":"45","author":"Jones","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt.37","article-title":"Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective","volume":"97","author":"Jones","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1742-7843.2005.pto_157.x","article-title":"Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin","volume":"97","author":"Kajosaari","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.119.087270_bib40","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-019-0341-y","article-title":"Guidance for rifampin and midazolam dosing protocols to study intestinal and hepatic cytochrome P450 (CYP) 3A4 induction and de-induction","volume":"21","author":"Kapetas","year":"2019","journal-title":"AAPS J"},{"key":"10.1124\/dmd.119.087270_bib42","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","article-title":"Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions","volume":"55","author":"Karlgren","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.119.087270_bib43","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0009-9236(98)90175-8","article-title":"Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam","volume":"64","author":"Kashuba","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib44","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2133\/dmpk.DMPK-09-RG-038","article-title":"Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans","volume":"25","author":"Kato","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.119.087270_bib45","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1124\/dmd.118.081927","article-title":"Considerations from the innovation and quality induction working group in response to drug-drug interaction guidances from regulatory agencies: focus on CYP3A4 mRNA in vitro response thresholds, variability, and clinical relevance","volume":"46","author":"Kenny","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib46","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1177\/00912709922008290","article-title":"Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance","volume":"39","author":"Kharasch","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib47","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/clpt.2010.313","article-title":"Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil","volume":"89","author":"Kharasch","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib48","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/cpt.856","article-title":"Identification of \u03c9- or (\u03c9-1)-hydroxylated medium-chain acylcarnitines as novel urinary biomarkers for CYP3A activity","volume":"103","author":"Kim","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib49","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/clpt.2011.336","article-title":"PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo","volume":"91","author":"Klein","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fgene.2013.00012","article-title":"Pharmacogenomics of cytochrome P450 3A4: recent progress toward the \u201cmissing heritability\u201d problem","volume":"4","author":"Klein","year":"2013","journal-title":"Front Genet"},{"key":"10.1124\/dmd.119.087270_bib51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/clpt.1982.133","article-title":"Physiologic and temporal variation in hepatic elimination of midazolam","volume":"32","author":"Klotz","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/phar.1388","article-title":"Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance","volume":"34","author":"Kwara","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.119.087270_bib53","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1124\/jpet.109.160804","article-title":"Genetic predictors of interindividual variability in hepatic CYP3A4 expression","volume":"332","author":"Lamba","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.087270_bib54","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/00008571-200112000-00006","article-title":"In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration","volume":"11","author":"Lin","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.119.087270_bib55","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00526-07","article-title":"Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects","volume":"51","author":"Liu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.119.087270_bib56","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/clpt.2008.64","article-title":"Plasma concentrations of oral oxycodone are greatly increased in the elderly","volume":"84","author":"Liukas","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib57","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2174\/1389200218666170531112038","article-title":"Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery","volume":"18","author":"Lolodi","year":"2017","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.119.087270_bib58","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/BF01733779","article-title":"Pharmacokinetics of oral and intravenous rifampicin during chronic administration","volume":"63","author":"Loos","year":"1985","journal-title":"Klin Wochenschr"},{"key":"10.1124\/dmd.119.087270_bib59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/03602532.2016.1239630","article-title":"Perspective: 4\u03b2-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A","volume":"49","author":"Mao","year":"2017","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.119.087270_bib60","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jcph.879","article-title":"Semisimultaneous midazolam administration to evaluate the time course of CYP3A activation by a single oral dose of efavirenz","volume":"57","author":"Mikus","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib61","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clpt.2006.04.004","article-title":"Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir","volume":"80","author":"Mikus","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jcpt.12016","article-title":"Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis","volume":"38","author":"Mil\u00e1n Segovia","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"10.1124\/dmd.119.087270_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mcp.2002.124519","article-title":"Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans","volume":"72","author":"Mouly","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1124\/dmd.119.087270_bib122","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2174\/1389200220666181128160813","article-title":"Progress in the Consideration of Possible Sex Differences in Drug Interaction Studies","volume":"20","author":"Naidoo","year":"2019","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.119.087270_bib64","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.bcp.2011.08.003","article-title":"Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine","volume":"82","author":"Nakajima","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib65","doi-asserted-by":"crossref","first-page":"20120431","DOI":"10.1098\/rstb.2012.0431","article-title":"Human cytochromes P450 in health and disease","volume":"368","author":"Nebert","year":"2013","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1124\/dmd.119.087270_bib66","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib67","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00008571-200007000-00001","article-title":"Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method","volume":"10","author":"Ozdemir","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.119.087270_bib68","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","article-title":"Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism","volume":"283","author":"Paine","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.087270_bib69","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/ajt.13059","article-title":"Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations","volume":"15","author":"Pallet","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1124\/dmd.119.087270_bib70","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1021\/tx700207u","article-title":"Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates","volume":"20","author":"Pearson","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.119.087270_bib71","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1208\/s12248-013-9470-x","article-title":"Drug-drug interaction studies: regulatory guidance and an industry perspective","volume":"15","author":"Prueksaritanont","year":"2013","journal-title":"AAPS J"},{"key":"10.1124\/dmd.119.087270_bib72","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/cpt.525","article-title":"Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A","volume":"101","author":"Prueksaritanont","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib73","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-3565(24)29202-8","article-title":"Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays","volume":"299","author":"Rae","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.087270_bib74","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1124\/dmd.115.065326","article-title":"Determination of a degradation constant for CYP3A4 by direct suppression of mRNA in a novel human hepatocyte model, hepatoPac","volume":"43","author":"Ramsden","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib75","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/dmd.32.3.364","article-title":"Is 17alpha-ethinyl estradiol an inhibitor of cytochrome P450 2C19?","volume":"32","author":"Rodrigues","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib76","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.01550-06","article-title":"Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients","volume":"51","author":"Ruslami","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.119.087270_bib77","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib78","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5414\/CPP38161","article-title":"P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans","volume":"38","author":"Schwarz","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib79","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1093\/jac\/dkv268","article-title":"Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults","volume":"70","author":"Seng","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.119.087270_bib80","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/0091270003262950","article-title":"Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity","volume":"44","author":"Shadle","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib81","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.1013","article-title":"Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective","volume":"104","author":"Shebley","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1124\/dmd.119.087270_bib124","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/psp4.30","article-title":"Physiologically Based Models in Regulatory Submissions: Output From the ABPI\/MHRA Forum on Physiologically Based Modeling and Simulation","volume":"4","author":"Shepard","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib82","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1124\/dmd.112.044883","article-title":"A novel polymorphic allele of human arylacetamide deacetylase leads to decreased enzyme activity","volume":"40","author":"Shimizu","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib83","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1074\/jbc.M008799200","article-title":"A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4","volume":"276","author":"Shou","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.119.087270_bib84","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40261-014-0217-y","article-title":"Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults","volume":"34","author":"Shumaker","year":"2014","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1124\/dmd.119.087270_bib123","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/cpt.406","article-title":"Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin","volume":"100","author":"Stopfer","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib85","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dky152","article-title":"Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis","volume":"73","author":"Stott","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.119.087270_bib86","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/dmd.117.075481","article-title":"Quantitative prediction of CYP3A4 induction: impact of measured, free, and intracellular perpetrator concentrations from human hepatocyte induction studies on drug-drug interaction predictions","volume":"45","author":"Sun","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib87","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/dmd.116.074393","article-title":"Applying stable Isotope labeled amino acids in micropatterned hepatocyte coculture to directly determine the degradation rate constant for CYP3A4","volume":"45","author":"Takahashi","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib88","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bcp.2012.03.017","article-title":"Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation","volume":"84","author":"Thirumaran","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib89","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0022-3565(25)22836-1","article-title":"Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation","volume":"271","author":"Thummel","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.087270_bib90","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/009127009903900508","article-title":"Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction","volume":"39","author":"Tran","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib91","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/clpt.2013.77","article-title":"Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium","volume":"94","author":"Tweedie","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib92","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/0091270007299930","article-title":"Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs","volume":"47","author":"Urquhart","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib93","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00228-018-2450-4","article-title":"Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries","volume":"74","author":"van Dyk","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib94","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/psp4.12007","article-title":"Population pharmacokinetic model characterizing 24-hour variation in the pharmacokinetics of oral and intravenous midazolam in healthy volunteers","volume":"4","author":"van Rongen","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib95","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s11095-012-0956-5","article-title":"Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide","volume":"30","author":"Varma","year":"2013","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.119.087270_bib96","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1124\/dmd.112.050583","article-title":"Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin","volume":"41","author":"Varma","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib97","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2002.34133","article-title":"Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver","volume":"36","author":"Vavricka","year":"2002","journal-title":"Hepatology"},{"key":"10.1124\/dmd.119.087270_bib98","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/dmd.105.004077","article-title":"In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude","volume":"33","author":"Venkatakrishnan","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib99","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/138920007780866861","article-title":"Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation","volume":"8","author":"Venkatakrishnan","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.119.087270_bib100","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/00498250701670945","article-title":"Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment","volume":"37","author":"Venkatakrishnan","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.119.087270_bib101","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0009-9236(97)90082-5","article-title":"Rifampin reduces plasma concentrations and effects of zolpidem","volume":"62","author":"Villikka","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib102","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","article-title":"Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy","volume":"13","author":"Wacher","year":"1995","journal-title":"Mol Carcinog"},{"key":"10.1124\/dmd.119.087270_bib103","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/psp4.33","article-title":"Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA Public Workshop on PBPK","volume":"4","author":"Wagner","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib104","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2010.28","article-title":"Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs","volume":"11","author":"Wang","year":"2011","journal-title":"Pharmacogenomic J"},{"key":"10.1124\/dmd.119.087270_bib105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsbmb.2012.09.012","article-title":"Interplay between vitamin D and the drug metabolizing enzyme CYP3A4","volume":"136","author":"Wang","year":"2013","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/dmd.119.087270_bib106","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2125.2002.01687.x","article-title":"Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?","volume":"54","author":"Wanwimolruk","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib107","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1172\/JCI113933","article-title":"Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients","volume":"83","author":"Watkins","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.119.087270_bib108","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.00461-07","article-title":"Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption","volume":"52","author":"Wilkins","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.119.087270_bib109","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.119.087270_bib110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3748\/wjg.v9.i2.359","article-title":"Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases","volume":"9","author":"Yang","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.1124\/dmd.119.087270_bib111","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1177\/0091270004269760","article-title":"Interindividual and intraindividual variability of the urinary 6beta-hydroxycortisol\/cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity","volume":"44","author":"Yin","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib112","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/cpt.622","article-title":"Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: frequent utilization in the field of oncology","volume":"101","author":"Yoshida","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.087270_bib113","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s11095-017-2168-5","article-title":"A clinical cassette dosing study for evaluating the contribution of hepatic OATPs and CYP3A to drug-drug interactions","volume":"34","author":"Yoshikado","year":"2017","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.119.087270_bib114","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1124\/dmd.114.060392","article-title":"Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review","volume":"42","author":"Yu","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/dmd.115.066720","article-title":"Key findings from preclinical and clinical drug interaction studies presented in new drug and biological license applications approved by the Food and Drug Administration in 2014","volume":"44","author":"Yu","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib116","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/dmd.116.073411","article-title":"What can be learned from recent new drug applications? A systematic review of drug interaction data for drugs approved by the US FDA in 2015","volume":"45","author":"Yu","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib117","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1124\/dmd.105.005447","article-title":"In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.087270_bib118","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cts.12499","article-title":"Role of CYP3A in oral contraceptives clearance","volume":"11","author":"Zhang","year":"2018","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1124\/dmd.119.087270_bib121","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/psp4.12166","article-title":"Report from the EMA workshop on qualification and reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation","volume":"6","author":"Zhao","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib119","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2125.2003.01728.x","article-title":"The distribution and gender difference of CYP3A activity in Chinese subjects","volume":"55","author":"Zhu","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.119.087270_bib120","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1124\/dmd.110.037911","article-title":"CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs","volume":"39","author":"Zimmerlin","year":"2011","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.119.087270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:03:28Z","timestamp":1739905408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624080346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":125,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0090955624080346"],"URL":"https:\/\/doi.org\/10.1124\/dmd.119.087270","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.119.087270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}